An Open, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of V221 Given Concomitantly With Pneumococcal Conjugate Vaccine in Healthy Children 12 to 15 Months of Age

Trial Profile

An Open, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of V221 Given Concomitantly With Pneumococcal Conjugate Vaccine in Healthy Children 12 to 15 Months of Age

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Apr 2017

At a glance

  • Drugs MMR-varicella zoster virus vaccine (Primary) ; Pneumococcal 7-valent CRM197 vaccine conjugate
  • Indications Chickenpox; Measles; Mumps; Pneumococcal infections; Rubella
  • Focus Pharmacodynamics
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 16 Feb 2010 Primary endpoints identified as reported by ClinicalTrials.gov.
    • 19 Feb 2009 Planned number of patients changed from 600 to 1027 as reported by ClinicalTrials.gov.
    • 03 Aug 2008 Additional trial identifier V221-019 reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top